Elizabeth Sigston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth Sigston has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
Annette M. Lim
Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia; University of Melbourne, Australia; Research Division, Peter MacCallum Cancer Centre, East Melbourne, Australia
3 shared publicationsChristopher Angel
Department of Pathology Peter MacCallum Cancer Centre East Melbourne Australia
3 shared publicationsDanny Rischin
Department of Medical Oncology Peter MacCallum Cancer Centre East Melbourne Australia
3 shared publications- David Wiesenfeld
Royal Melbourne Hosp, Dept Surg, Head & Neck Tumour Stream, Parkville, Vic, Australia
3 shared publications June Corry
University of Melbourne Australia
3 shared publicationsMarnie Collins
Department of Biostatistics and Clinical Trials Peter MacCallum Cancer Centre East Melbourne Australia
3 shared publications
Latest Publications
- Open Access
Systems and organisational change to advance gender equity in healthcare leadership: a mixed-methods protocol
Background: Despite comprising over 70% of the global healthcare workforce, women remain significantly underrepresented in healthcare leadership. Structural and systemic barriers persist across academic medicine, health services, and professional organisations, limiting career progression and leadership opportunities for women. Existing efforts often focus on individual-level interventions, overlooking the broader organisational and systemic contexts that shape leadership pathways. Urgent, coordinated action is needed to address gender inequity through sustainable, evidence-informed systems change. Methods: This protocol outlines the Organisation Change Management (OCM) workstream within the Australian Advancing Women in Healthcare Leadership (AWHL) initiative—a nationally implemented, multi-sector partnership. The initiative applies a mixed-methods, coproduction approach to implement and evaluate multi-level interventions aimed at advancing gender equity in healthcare leadership. Guided by the Consolidated Framework for Implementation Research, the Learning Health System framework, and the Reach, Effectiveness, Adoption, Implementation and Maintenance evaluation model, the study engages stakeholders across outer (policy, regulation, funding) and inner (organisational culture, leadership structures) settings to drive systemic and organisational changes to enhance gender equity in leadership. Data collection includes administrative datasets and policy documents, semi-structured interviews, and surveys across partner organisations. Findings will inform tailored interventions and an implementation toolkit, developed and evaluated through iterative stakeholder engagement. Discussion: This is the first national initiative to apply a systems-level, coproduced approach to gender equity in healthcare leadership, engaging strategic partners including health services, professional colleges and associations, government, and women in the workforce. By leveraging implementation science and systems change methodologies, the initiative aims to accelerate sustainable organisational transformation. The protocol provides a replicable framework for advancing equity in healthcare leadership and beyond.
Open AccessSystems and organisational change to advance gender equity in healthcare leadership: a mixed-methods protocol
Background: Despite comprising over 70% of the global healthcare workforce, women remain significantly underrepresented in healthcare leadership. Structural and systemic barriers persist across academic medicine, health services, and professional organisations, limiting career progression and leadership opportunities for women. Existing efforts often focus on individual-level interventions, overlooking the broader organisational and systemic contexts that shape leadership pathways. Urgent, coordinated action is needed to address gender inequity through sustainable, evidence-informed systems change. Methods: This protocol outlines the Organisation Change Management (OCM) workstream within the Australian Advancing Women in Healthcare Leadership (AWHL) initiative—a nationally implemented, multi-sector partnership. The initiative applies a mixed-methods, coproduction approach to implement and evaluate multi-level interventions aimed at advancing gender equity in healthcare leadership. Guided by the Consolidated Framework for Implementation Research, the Learning Health System framework, and the Reach, Effectiveness, Adoption, Implementation and Maintenance evaluation model, the study engages stakeholders across outer (policy, regulation, funding) and inner (organisational culture, leadership structures) settings to drive systemic and organisational changes to enhance gender equity in leadership. Data collection includes administrative datasets and policy documents, semi-structured interviews, and surveys across partner organisations. Findings will inform tailored interventions and an implementation toolkit, developed and evaluated through iterative stakeholder engagement. Discussion: This is the first national initiative to apply a systems-level, coproduced approach to gender equity in healthcare leadership, engaging strategic partners including health services, professional colleges and associations, government, and women in the workforce. By leveraging implementation science and systems change methodologies, the initiative aims to accelerate sustainable organisational transformation. The protocol provides a replicable framework for advancing equity in healthcare leadership and beyond.
- Open Access
- 10 December 2021
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 9, 640611
How 3D Printing Is Reshaping Translational Research
“Translational Research” has traditionally been defined as taking basic scientific findings and developing new diagnostic tools, drugs, devices and treatment options for patients, that are translated into practice, reach the people and populations for whom they are intended and are implemented correctly. The implication is of a unidirectional flow from “the bench to bedside”. The rapidly emergent field of additive manufacturing (3D printing) is contributing to a major shift in translational medical research. This includes the concept of bidirectional or reverse translation, early collaboration between clinicians, bio-engineers and basic scientists, and an increasingly entrepreneurial mindset. This coincides with, and is strongly complemented by, the rise of systems biology. The rapid pace at which this type of translational research can occur brings a variety of potential pitfalls and ethical concerns. Regulation surrounding implantable medical devices is struggling to keep up. 3D printing has opened the way for personalization which can make clinical outcomes hard to assess and risks putting the individual before the community. In some instances, novelty and hype has led to loss of transparency of outcomes with dire consequence. Collaboration with commercial partners has potential for conflict of interest. Nevertheless, 3D printing has dramatically changed the landscape of translational research. With early recognition and management of the potential risks, the benefits of reshaping the approach to translational research are enormous. This impact will extend into many other areas of biomedical research, re-establishing that science is more than a body of research. It is a way of thinking.
- 10 December 2021
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 9, 640611
Open AccessHow 3D Printing Is Reshaping Translational Research
“Translational Research” has traditionally been defined as taking basic scientific findings and developing new diagnostic tools, drugs, devices and treatment options for patients, that are translated into practice, reach the people and populations for whom they are intended and are implemented correctly. The implication is of a unidirectional flow from “the bench to bedside”. The rapidly emergent field of additive manufacturing (3D printing) is contributing to a major shift in translational medical research. This includes the concept of bidirectional or reverse translation, early collaboration between clinicians, bio-engineers and basic scientists, and an increasingly entrepreneurial mindset. This coincides with, and is strongly complemented by, the rise of systems biology. The rapid pace at which this type of translational research can occur brings a variety of potential pitfalls and ethical concerns. Regulation surrounding implantable medical devices is struggling to keep up. 3D printing has opened the way for personalization which can make clinical outcomes hard to assess and risks putting the individual before the community. In some instances, novelty and hype has led to loss of transparency of outcomes with dire consequence. Collaboration with commercial partners has potential for conflict of interest. Nevertheless, 3D printing has dramatically changed the landscape of translational research. With early recognition and management of the potential risks, the benefits of reshaping the approach to translational research are enormous. This impact will extend into many other areas of biomedical research, re-establishing that science is more than a body of research. It is a way of thinking.
- 7 May 2020
- Published by SAGE Publications in Thyroid®
- Vol. 30 (5) , 785-786
Re: “Routine Preoperative Laryngoscopy for Thyroid Surgery Is Not Necessary Without Risk Factors” by Maher et al. (Thyroid 2019;29:1646–1652. DOI: 10.1089/thy.2019.0145)
- 7 May 2020
- Published by SAGE Publications in Thyroid®
- Vol. 30 (5) , 785-786
Re: “Routine Preoperative Laryngoscopy for Thyroid Surgery Is Not Necessary Without Risk Factors” by Maher et al. (Thyroid 2019;29:1646–1652. DOI: 10.1089/thy.2019.0145)
- 1 January 2019
- Published by AME Publishing Company in Australian Journal of Otolaryngology
- Vol. 2
Outcomes using the T-14 symptom score for tonsillectomy in an Australian paediatric population
Background: Quality of life (QoL) outcomes afterpaediatric tonsillectomy can be assessed with disease-specific patient reportedoutcome measures. Our aim was to assess a modified T-14 Paediatric ThroatDisorders Outcome Test in an Australian paediatric population undergoing tonsillectomy. Methods: A consecutive case series wasconducted in children (aged 1–16 years) undergoing tonsillectomy over a periodof 15 months. T-14 questionnaires administered to the caregivers of the childpre-operatively and post-operatively (n=45) within 6–8 weeks of the procedurewere included for statistical analysis. Pre- and post-operative T-14 scoreswere compared and analysed according to surgical indication [either sleepdisordered breathing (SDB), recurrent tonsillitis, or both] and complicationswith non-parametric tests. Results: Post-operative scores demonstrated aglobal improvement for SDB (n=22), recurrent tonsillitis (n=12) and for both(n=11) indications (PConclusions: The modified T-14 questionnaire issuitable for measuring parental reported health outcomes for paediatric throatdisorders in patients undergoing tonsillectomy in the Australian population.The T-14 questionnaire demonstrates improvement in parental perception of theirchild’s symptoms after tonsillectomy. It is easy to administer producing a highcompliance rate.
- 1 January 2019
- Published by AME Publishing Company in Australian Journal of Otolaryngology
- Vol. 2
Outcomes using the T-14 symptom score for tonsillectomy in an Australian paediatric population
Background: Quality of life (QoL) outcomes afterpaediatric tonsillectomy can be assessed with disease-specific patient reportedoutcome measures. Our aim was to assess a modified T-14 Paediatric ThroatDisorders Outcome Test in an Australian paediatric population undergoing tonsillectomy. Methods: A consecutive case series wasconducted in children (aged 1–16 years) undergoing tonsillectomy over a periodof 15 months. T-14 questionnaires administered to the caregivers of the childpre-operatively and post-operatively (n=45) within 6–8 weeks of the procedurewere included for statistical analysis. Pre- and post-operative T-14 scoreswere compared and analysed according to surgical indication [either sleepdisordered breathing (SDB), recurrent tonsillitis, or both] and complicationswith non-parametric tests. Results: Post-operative scores demonstrated aglobal improvement for SDB (n=22), recurrent tonsillitis (n=12) and for both(n=11) indications (PConclusions: The modified T-14 questionnaire issuitable for measuring parental reported health outcomes for paediatric throatdisorders in patients undergoing tonsillectomy in the Australian population.The T-14 questionnaire demonstrates improvement in parental perception of theirchild’s symptoms after tonsillectomy. It is easy to administer producing a highcompliance rate.
- Open Access
- 14 September 2017
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 7, 198
An Emergence Framework of Carcinogenesis
Experimental paradigms provide the framework for the understanding of cancer, and drive research and treatment, but are rarely considered by clinicians. The Somatic Mutation Theory (SMT), in which cancer is considered a genetic disease, has been the predominant traditional model of cancer for over fifty years. More recently alternative theories have been proposed, such as Tissue Organization Field Theory (TOFT), evolutionary models and inflammatory models. Key concepts within the various models have led to them being difficult to reconcile. Progressively, it has been recognized that biological systems cannot be fully explained by the physicochemical properties of their constituent parts. There is an increasing call for a ‘systems’ approach. Incorporating the concepts of ‘emergence’, ‘systems’, ‘thermodynamics’ and ‘chaos’, a single integrated framework for carcinogenesis has been developed, enabling existing theories to become compatible as alternative mechanisms, facilitating the integration of bioinformatics and providing a structure in which translational research can flow from both ‘benchtop to bedside’ and ‘bedside to benchtop’. In this review, a basic understanding of the key concepts of ‘emergence’, ‘systems’, ‘system levels’, ‘complexity’, ‘thermodynamics’, ‘entropy’, ‘chaos’ and ‘fractals’ is provided. Nonlinear mathematical equations are included where possible to demonstrate compatibility with bioinformatics. Twelve postulates that define the ‘emergence framework of carcinogenesis’ are developed, with postulates 1–10 encapsulating the key concepts upon which the framework is built and their application to carcinogenesis. Postulate 11 relates the framework to cancer progression. The 12th postulate relates to the application of the framework to translational research. The ‘emergence framework of carcinogenesis’ collates current paradigms, concepts and evidence around carcinogenesis into a single framework that incorporates previously incompatible viewpoints and ideas. Any researcher, scientist or clinician involved in research, treatment or prevention of cancer can employ this framework.
- 14 September 2017
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 7, 198
Open AccessAn Emergence Framework of Carcinogenesis
Experimental paradigms provide the framework for the understanding of cancer, and drive research and treatment, but are rarely considered by clinicians. The Somatic Mutation Theory (SMT), in which cancer is considered a genetic disease, has been the predominant traditional model of cancer for over fifty years. More recently alternative theories have been proposed, such as Tissue Organization Field Theory (TOFT), evolutionary models and inflammatory models. Key concepts within the various models have led to them being difficult to reconcile. Progressively, it has been recognized that biological systems cannot be fully explained by the physicochemical properties of their constituent parts. There is an increasing call for a ‘systems’ approach. Incorporating the concepts of ‘emergence’, ‘systems’, ‘thermodynamics’ and ‘chaos’, a single integrated framework for carcinogenesis has been developed, enabling existing theories to become compatible as alternative mechanisms, facilitating the integration of bioinformatics and providing a structure in which translational research can flow from both ‘benchtop to bedside’ and ‘bedside to benchtop’. In this review, a basic understanding of the key concepts of ‘emergence’, ‘systems’, ‘system levels’, ‘complexity’, ‘thermodynamics’, ‘entropy’, ‘chaos’ and ‘fractals’ is provided. Nonlinear mathematical equations are included where possible to demonstrate compatibility with bioinformatics. Twelve postulates that define the ‘emergence framework of carcinogenesis’ are developed, with postulates 1–10 encapsulating the key concepts upon which the framework is built and their application to carcinogenesis. Postulate 11 relates the framework to cancer progression. The 12th postulate relates to the application of the framework to translational research. The ‘emergence framework of carcinogenesis’ collates current paradigms, concepts and evidence around carcinogenesis into a single framework that incorporates previously incompatible viewpoints and ideas. Any researcher, scientist or clinician involved in research, treatment or prevention of cancer can employ this framework.
- Open Access
- 8 November 2016
- Published by Springer Nature in Cancer Imaging
- Vol. 16 (1) , 1-8
Utility of SUVmax on 18 F-FDG PET in detecting cervical nodal metastases
The presence of cervical lymph node metastasis is an important prognostic factor for patients with head and neck squamous cell carcinomas (HNSCC). Accurate assessment of lymph node metastasis in these patients is essential for appropriate prognostic and management purposes. Here, we evaluated the effectiveness of the maximum standardized uptake value (SUVmax) on positron emission tomography (PET) in assessing lymph node metastasis in HNSCC prior to surgery. A retrospective review of 74 patients with HNSCC who underwent PET/CT prior to neck dissection were examined. Pre-operative PET/CT scans were reviewed by two experienced nuclear medicine physicians and SUVmax of the largest node in each nodal basin documented. These were compared with the histology results of the neck dissection. A total of 359 nodal basins including 86 basins with metastatic nodes were evaluated. A nodal SUVmax ≥3.16 yielded a sensitivity of 74.4 % and specificity of 84.9 % in detecting metastatic nodes. The nodal SUVmax/Liver SUVmax ratio was found on receiver operating characteristic (ROC) to be effective in detecting metastatic nodes with an area under ROC curve of 0.90. A nodal SUVmax/Liver SUVmax ratio ≥0.90 yielded a sensitivity of 74.1 % and specificity of 93.4 %. By comparison, visual inspection yielded sensitivities of 66.3 and 61.6 % in observers 1 and 2 respectively. The corresponding specificities were 77.7 and 86.5 %. Nodal SUVmax and nodal SUVmax/liver SUVmax are both useful in the pre-operative detection of metastatic nodes with the latter being superior to visual inspection. The ratio is likely to be more useful as it corrects for inter-scanner variability.
- 8 November 2016
- Published by Springer Nature in Cancer Imaging
- Vol. 16 (1) , 1-8
Open AccessUtility of SUVmax on 18 F-FDG PET in detecting cervical nodal metastases
The presence of cervical lymph node metastasis is an important prognostic factor for patients with head and neck squamous cell carcinomas (HNSCC). Accurate assessment of lymph node metastasis in these patients is essential for appropriate prognostic and management purposes. Here, we evaluated the effectiveness of the maximum standardized uptake value (SUVmax) on positron emission tomography (PET) in assessing lymph node metastasis in HNSCC prior to surgery. A retrospective review of 74 patients with HNSCC who underwent PET/CT prior to neck dissection were examined. Pre-operative PET/CT scans were reviewed by two experienced nuclear medicine physicians and SUVmax of the largest node in each nodal basin documented. These were compared with the histology results of the neck dissection. A total of 359 nodal basins including 86 basins with metastatic nodes were evaluated. A nodal SUVmax ≥3.16 yielded a sensitivity of 74.4 % and specificity of 84.9 % in detecting metastatic nodes. The nodal SUVmax/Liver SUVmax ratio was found on receiver operating characteristic (ROC) to be effective in detecting metastatic nodes with an area under ROC curve of 0.90. A nodal SUVmax/Liver SUVmax ratio ≥0.90 yielded a sensitivity of 74.1 % and specificity of 93.4 %. By comparison, visual inspection yielded sensitivities of 66.3 and 61.6 % in observers 1 and 2 respectively. The corresponding specificities were 77.7 and 86.5 %. Nodal SUVmax and nodal SUVmax/liver SUVmax are both useful in the pre-operative detection of metastatic nodes with the latter being superior to visual inspection. The ratio is likely to be more useful as it corrects for inter-scanner variability.
- 27 October 2016
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 131 (S1) , S36-S40
Do demographics and tumour-related factors affect nodal yield at neck dissection? A retrospective cohort study
Background: Nodal metastasis is an important prognostic factor in head and neck squamous cell carcinoma. This study aimed to determine the average nodal basin yield per level of neck dissection, and to investigate if age, gender, body mass index, tumour size, depth of tumour invasion and p16 status influence nodal yield. Method: A retrospective review of 185 patients with head and neck squamous cell carcinoma generated 240 neck dissection specimens. Results: The respective mean nodal yields for levels I, II, III, IV and V were 5.27, 9.43, 8.49, 7.43 and 9.02 in non-cutaneous squamous cell carcinoma patients, and 4.2, 7.57, 9.65, 4.33 and 12.29 in cutaneous squamous cell carcinoma patients. Multiple regression analysis revealed that p16-positive patients with mucosal squamous cell carcinoma yielded, on average, 2.4 more nodes than their p16-negative peers (p = 0.04, 95 per cent confidence interval = 0.116 to 4.693). This figure was 3.84 (p = 0.008, 95 per cent confidence interval = 1.070 to 6.605) for p16-positive patients with oral cavity squamous cell carcinoma. Conclusion: In mucosal squamous cell carcinoma, p16-positive status significantly influenced nodal yield, with the impact being more pronounced in oral cavity squamous cell carcinoma patients.
- 27 October 2016
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 131 (S1) , S36-S40
Do demographics and tumour-related factors affect nodal yield at neck dissection? A retrospective cohort study
Background: Nodal metastasis is an important prognostic factor in head and neck squamous cell carcinoma. This study aimed to determine the average nodal basin yield per level of neck dissection, and to investigate if age, gender, body mass index, tumour size, depth of tumour invasion and p16 status influence nodal yield. Method: A retrospective review of 185 patients with head and neck squamous cell carcinoma generated 240 neck dissection specimens. Results: The respective mean nodal yields for levels I, II, III, IV and V were 5.27, 9.43, 8.49, 7.43 and 9.02 in non-cutaneous squamous cell carcinoma patients, and 4.2, 7.57, 9.65, 4.33 and 12.29 in cutaneous squamous cell carcinoma patients. Multiple regression analysis revealed that p16-positive patients with mucosal squamous cell carcinoma yielded, on average, 2.4 more nodes than their p16-negative peers (p = 0.04, 95 per cent confidence interval = 0.116 to 4.693). This figure was 3.84 (p = 0.008, 95 per cent confidence interval = 1.070 to 6.605) for p16-positive patients with oral cavity squamous cell carcinoma. Conclusion: In mucosal squamous cell carcinoma, p16-positive status significantly influenced nodal yield, with the impact being more pronounced in oral cavity squamous cell carcinoma patients.
- 4 April 2016
- Published by Wiley in Head & Neck
- Vol. 38 (9) , 1401-1406
Surgical margins in head and neck squamous cell carcinoma: Effect of heat artifact on immunohistochemistry as a future tool for assessment
Background: Margins in head and neck squamous cell carcinoma (HNSCC) are determined by morphological changes assessed via hematoxylin‐eosin staining. Physiological changes may not be detected by this technique. The purpose of this study was to determine if a protein biomarker, laminin‐332γ2, overexpressed in cancer cells at the invasive front in HNSCC, remains unaffected by heat produced during resection, supporting a role for immunohistochemistry assessment of margins.Methods: Archived tissue blocks from glottic squamous cell carcinomas (SCCs) resected by CO2 laser likely to contain both cancer cells and artifact were identified; 129‐paired slides were obtained. One slide of each pair was stained with hematoxylin‐eosin; the second stained for laminin‐332γ2. The presence of cancer cells, artifact, and positive laminin‐332γ2 staining was recorded. Twenty‐seven pairs met the inclusion criteria.Results: Immunohistochemistry staining of laminin‐332γ is preserved in presence of heat artifact.Conclusion: This study supports use of immunohistochemistry to assess margins. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1401–1406, 2016
- 4 April 2016
- Published by Wiley in Head & Neck
- Vol. 38 (9) , 1401-1406
Surgical margins in head and neck squamous cell carcinoma: Effect of heat artifact on immunohistochemistry as a future tool for assessment
Background: Margins in head and neck squamous cell carcinoma (HNSCC) are determined by morphological changes assessed via hematoxylin‐eosin staining. Physiological changes may not be detected by this technique. The purpose of this study was to determine if a protein biomarker, laminin‐332γ2, overexpressed in cancer cells at the invasive front in HNSCC, remains unaffected by heat produced during resection, supporting a role for immunohistochemistry assessment of margins.Methods: Archived tissue blocks from glottic squamous cell carcinomas (SCCs) resected by CO2 laser likely to contain both cancer cells and artifact were identified; 129‐paired slides were obtained. One slide of each pair was stained with hematoxylin‐eosin; the second stained for laminin‐332γ2. The presence of cancer cells, artifact, and positive laminin‐332γ2 staining was recorded. Twenty‐seven pairs met the inclusion criteria.Results: Immunohistochemistry staining of laminin‐332γ is preserved in presence of heat artifact.Conclusion: This study supports use of immunohistochemistry to assess margins. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1401–1406, 2016
- Open Access
- 9 December 2014
- Published by Springer Nature in Clinical Epigenetics
- Vol. 6 (1) , 22
Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome
DNA hypermethylation is reported as a frequent event and prognostic marker in head and neck squamous cell carcinomas (HNSCC). Methylation has been commonly assessed with non-quantitative methodologies, such as methylation-specific PCR (MSP). We investigated previously reported hypermethylated genes with quantitative methodology in oral tongue squamous cell carcinomas (OTSCC). The methylation status of 12 genes in 115 OTSCC samples was assessed by one or more of three quantitative analyses: methylation sensitive high resolution melting (MS-HRM), sensitive-melting analysis after real time-methylation specific PCR (SMART-MSP), and bisulfite pyrosequencing. In contrast to much of the literature, either no or infrequent locus-specific methylation was identified by MS-HRM for DAPK1, RASSF1A, MGMT, MLH1, APC, CDH1, CDH13, BRCA1, ERCC1, and ATM. The most frequently methylated loci were RUNX3 (18/108 methylated) and ABO (22/107 methylated). Interrogation of the Cancer Genome Atlas (TCGA) HNSCC cohort confirmed the frequency of significant methylation for the loci investigated. Heterogeneous methylation of RUNX3 (18/108) and ABO (22/107) detected by MS-HRM, conferred significantly worse survival (P = 0.01, and P = 0.03). However, following quantification of methylation levels using pyrosequencing, only four tumors had significant quantities (>15%) of RUNX3 methylation which correlated with a worse patient outcome (P <0.001), while the prognostic significance of ABO hypermethylation was lost. RUNX3 methylation was not prognostic for the TCGA cohort (P = 0.76). We demonstrated the critical need for quantification of methylation levels and its impact on correlative analyses. In OTSCC, we found little evidence of significant or frequent hypermethylation of many loci reported to be commonly methylated. It is likely that previous reports have overestimated the frequency of significant methylation events as a consequence of the use of non-quantitative methodology.
- 9 December 2014
- Published by Springer Nature in Clinical Epigenetics
- Vol. 6 (1) , 22
Open AccessQuantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome
DNA hypermethylation is reported as a frequent event and prognostic marker in head and neck squamous cell carcinomas (HNSCC). Methylation has been commonly assessed with non-quantitative methodologies, such as methylation-specific PCR (MSP). We investigated previously reported hypermethylated genes with quantitative methodology in oral tongue squamous cell carcinomas (OTSCC). The methylation status of 12 genes in 115 OTSCC samples was assessed by one or more of three quantitative analyses: methylation sensitive high resolution melting (MS-HRM), sensitive-melting analysis after real time-methylation specific PCR (SMART-MSP), and bisulfite pyrosequencing. In contrast to much of the literature, either no or infrequent locus-specific methylation was identified by MS-HRM for DAPK1, RASSF1A, MGMT, MLH1, APC, CDH1, CDH13, BRCA1, ERCC1, and ATM. The most frequently methylated loci were RUNX3 (18/108 methylated) and ABO (22/107 methylated). Interrogation of the Cancer Genome Atlas (TCGA) HNSCC cohort confirmed the frequency of significant methylation for the loci investigated. Heterogeneous methylation of RUNX3 (18/108) and ABO (22/107) detected by MS-HRM, conferred significantly worse survival (P = 0.01, and P = 0.03). However, following quantification of methylation levels using pyrosequencing, only four tumors had significant quantities (>15%) of RUNX3 methylation which correlated with a worse patient outcome (P <0.001), while the prognostic significance of ABO hypermethylation was lost. RUNX3 methylation was not prognostic for the TCGA cohort (P = 0.76). We demonstrated the critical need for quantification of methylation levels and its impact on correlative analyses. In OTSCC, we found little evidence of significant or frequent hypermethylation of many loci reported to be commonly methylated. It is likely that previous reports have overestimated the frequency of significant methylation events as a consequence of the use of non-quantitative methodology.
- Open Access
- 16 January 2014
- Published by Wiley in International Journal of Cancer
- Vol. 135 (4) , 887-895
Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome
CDKN2A (p16) disruption is reported as a frequent event in head and neck squamous cell carcinomas that confers poor prognosis. We investigated the frequency of different potential mechanisms of CDKN2A inactivation in oral tongue squamous cell carcinomas (OTSCC) and their impact on patient outcome. From a cohort of 153 OTSCC patients, 131 formalin fixed paraffin embedded blocks of pre‐treatment primary tumours were suitable for further molecular analysis. We assessed CDKN2A (p16) levels by immunohistochemistry (IHC), promoter methylation status by methylation‐sensitive high resolution melting, mutation status by Sanger sequencing, gene copy number variation by fluorescence in situ hybridisation, and correlated these with patient outcome. We found that the majority of OTSCC did not overexpress p16 (110/116, 95%), assessed by IHC. The frequency of CDKN2A mutations was 20% (21/103), homozygous loss was 7% (7/97), hemizygous loss 31% (30/97), and promoter methylation was 18% (20/113). We found no evidence of these mechanisms in 24/106 (23%) p16 IHC negative tumours. No significant correlation was identified between any potential mechanism of CDKN2A inactivation and clinical features, including smoking status and age. There was a non‐significant trend for worse overall survival for p16 IHC negative patients versus positive patients (HR = 1.81, 95% CI = 0.44–7.47, p = 0.40). No relationship was found between mechanisms of CDKN2A disruption and patient outcome. In conclusion, we demonstrate that CDKN2A alteration is a frequent event in OTSCC tumourigenesis. However, no correlation was identified between different potential mechanisms of CDKN2A disruption and clinical characteristics or patient outcome.
- 16 January 2014
- Published by Wiley in International Journal of Cancer
- Vol. 135 (4) , 887-895
Open AccessDifferential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome
CDKN2A (p16) disruption is reported as a frequent event in head and neck squamous cell carcinomas that confers poor prognosis. We investigated the frequency of different potential mechanisms of CDKN2A inactivation in oral tongue squamous cell carcinomas (OTSCC) and their impact on patient outcome. From a cohort of 153 OTSCC patients, 131 formalin fixed paraffin embedded blocks of pre‐treatment primary tumours were suitable for further molecular analysis. We assessed CDKN2A (p16) levels by immunohistochemistry (IHC), promoter methylation status by methylation‐sensitive high resolution melting, mutation status by Sanger sequencing, gene copy number variation by fluorescence in situ hybridisation, and correlated these with patient outcome. We found that the majority of OTSCC did not overexpress p16 (110/116, 95%), assessed by IHC. The frequency of CDKN2A mutations was 20% (21/103), homozygous loss was 7% (7/97), hemizygous loss 31% (30/97), and promoter methylation was 18% (20/113). We found no evidence of these mechanisms in 24/106 (23%) p16 IHC negative tumours. No significant correlation was identified between any potential mechanism of CDKN2A inactivation and clinical features, including smoking status and age. There was a non‐significant trend for worse overall survival for p16 IHC negative patients versus positive patients (HR = 1.81, 95% CI = 0.44–7.47, p = 0.40). No relationship was found between mechanisms of CDKN2A disruption and patient outcome. In conclusion, we demonstrate that CDKN2A alteration is a frequent event in OTSCC tumourigenesis. However, no correlation was identified between different potential mechanisms of CDKN2A disruption and clinical characteristics or patient outcome.